ERBB2 and breast cancer: From a biological perspective, this could be attributed to the co-expression of HoR (7, 11) and a low level of HER2 expression, which might be a therapeutic resistance factor (12) in HoR-positive BC due to the interplay between HoR-signaling and HER2 signaling.